1. Salutaris Medical Devices developed a Radionuclide Brachytherapy Source tool for episcleral brachytherapy — the treatment of a specific type of eye cancer.
2. Rubraca is an ovarian cancer drug for women with a BRCA gene mutation who have already been treated with two or more chemotherapies.
3. Eucrisa is intended to treat mild to moderate cases of eczema.
4. Cepheid’s Xpert MRSA NxG test can detect methicillin-resistant Staphylococcus aureus in about one hour.
5. The AeroForm tissue expander system is used to stretch out breast tissue in preparation for a two-stage breast reconstruction following a mastectomy.
More articles on supply chain:
Salutaris’ brachytherapy device earns FDA market clearance
Champlain Valley Physicians Hospital undergoing critical blood shortage
Senate committee releases comprehensive report on high drug prices: 4 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.